Testing the Toxicity of Cancer Drugs on Blood Cells
Author Information
Author(s): M Ghielmini, G Bosshard, L Capolongo, M C Geroni, E Pesenti, V Torri, M D'Incalci, F Cavalil, C Sessal
Hypothesis
Can human cord blood cells be used to evaluate the myelotoxicity of minor groove alkylators?
Conclusion
Human cord blood cells can effectively replace bone marrow cells for testing the myelotoxicity of certain cancer drugs.
Supporting Evidence
- Clonogenic assays showed similar toxicity results for tallimustine on both bone marrow and cord blood cells.
- Carzelesin was identified as the most potent drug among those tested.
- The in vitro therapeutic index of carzelesin was significantly higher than that of other compounds.
- ID70 values for tallimustine were comparable to concentrations found in patients treated at maximum tolerated doses.
Takeaway
Scientists tested new cancer drugs on blood cells from umbilical cords instead of bone marrow, and found that the results were similar, which could help in drug development.
Methodology
Clonogenic assays were performed on human bone marrow and cord blood cells to evaluate drug toxicity.
Limitations
The study may not account for all interspecies variations in drug response.
Participant Demographics
Seven normal volunteers aged 32-45 provided bone marrow samples, and 14 cord blood samples were collected from placentas after vaginal deliveries.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website